COVID-19 vaccines have been developed with unprecedented speed which would not have
been possible without decades of fundamental research on delivery nanotechnology. Lipid …

Solid–lipid nanoparticles and nanostructured lipid carriers are delivery systems for the
delivery of drugs and other bioactives used in diagnosis, therapy, and treatment procedures …

Acetaminophen (APAP)-induced liver injury (AILI) is a common liver disease in clinical
practice. Only one clinically approved drug, N-acetylcysteine (NAC), for the treatment of AILI …

In the development of central nervous system (CNS) drugs, the blood–brain barrier (BBB)
restricts many drugs from entering the brain to exert therapeutic effects. Although many …

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

The era of the aging society has arrived, and this is accompanied by an increase in the
absolute numbers of patients with neurological disorders, such as Alzheimer's disease (AD) …

Multiple sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease of the central
nervous system (CNS) that yields to neuronal axon damage, demyelization, and paralysis …

Migraine is a severe neurovascular disease manifested mainly as unilateral throbbing
headaches. Triptans are agonists for serotonin receptors. Zolmitriptan (ZMP) is a …

Glioblastoma (GBL) is the most common (60–70% of primary brain tumours) and the most
malignant of the glial tumours. Although current therapies remain palliative, they have been …

In an attempt to develop drug delivery systems that bypass the blood–brain barrier (BBB)
and prevent liver and intestinal degradation, it was concluded that nasal medication meets …